Qiagen NV | QIA

Stock Price
40.39
Daily Change
0.18 0.44%
Monthly
-1.72%
Yearly
-1.38%
Q3 Forecast
40.13

Peers Price Chg Day Year Date
Avita Medical 1.34 0.01 0.75% -48.46% Sep/05
argenx SE 639.80 8.40 1.33% 31.21% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
IQVIA Holdings 187.68 3.60 1.96% -22.83% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Organon & Co 10.38 0.70 7.23% -49.40% Sep/05
Revvity 86.64 0.94 1.10% -24.90% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Viatris 10.50 0.17 1.65% -6.87% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
DE40 23597 -173.35 -0.73% 28.93% Sep/05
EU600 549 -0.88 -0.16% 8.42% Sep/05

Qiagen NV traded at 40.39 this Saturday September 6th, increasing 0.18 or 0.44 percent since the previous trading session. Looking back, over the last four weeks, Qiagen NV gained 1.72 percent. Over the last 12 months, its price fell by 1.38 percent. Looking ahead, we forecast Qiagen NV to be priced at 40.13 by the end of this quarter and at 39.37 in one year, according to Trading Economics global macro models projections and analysts expectations.

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.